GRIPHON—The FIRST and ONLY COMPLETED PAH Outcomes Trial That Included Patients Treated With TRIPLE-Combination Therapy1

UPTRAVI® campaign 3
  • Multicenter, long-term, double-blind, placebo-controlled, parallel-group, event-driven, phase 3 trial
1156 patients with symptomatic PAH (UPTRAVI®: n=574; placebo: n=582) mobile study design for GRIPHON

After the starting dose of 200 mcg twice daily, all patients completed titration to their maintenance dose within the first 12 weeks, up to a maximum dose of 1600 mcg twice daily.

Primary endpoint: time to first PAH disease progression event

  • Death
  • Hospitalization for PAH
  • Need for lung transplantation or balloon atrial septostomy for worsening of PAH
  • Parenteral prostanoid or
    chronic oxygen therapy
  • Other disease progression (decrease in 6MWD plus worsening of FC or need for other therapy)

Baseline patient characteristics

  • Mean age: 48 years
  • Female: 80%
80% on PAH background therapy pie chart
Nearly 1/2 of all patients were FC II pie chart
Etiology: idiopathic or heritable PAH (58%), PAH-CTD (29%), PAH-CHD (10%), other (3%)

This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI® (selexipag). Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc. or its affiliates.